A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease Letter uri icon

Overview

MeSH Major

  • Cancer Vaccines
  • Fusion Proteins, bcr-abl
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

publication date

  • August 20, 2008

Research

keywords

  • Letter

Identity

Digital Object Identifier (DOI)

  • 10.1038/leu.2008.7

PubMed ID

  • 18256684

Additional Document Info

start page

  • 1613

end page

  • 6

volume

  • 22

number

  • 8